The National Institute for Health Research
funded a large international study (the CRASH-2 trial)
that showed that, if used within three hours after trauma, TXA can
reduce the risk of death from bleeding by as much as 30
per cent.
Based on these findings, getting the drug to
trauma patients could save around 400
lives per year in the UK. The drug was quickly moved
into routine practice by trauma teams in the military
but the challenge was how best to get TXA used in the
NHS ambulance service and in hospital trusts.